Table 1.
Patient and patient tumor characteristics.
| Variable | All patients | Adenocarcinoma | Squamous cell carcinoma | P | |||
|---|---|---|---|---|---|---|---|
| N | Summary stats | N | Summary stats | N | Summary stats | ||
| Total number of patients | 7606 | – | 5523 | – | 2083 | – | – |
| Gender (N, %) | 7603 | 5521 | 2082 | ||||
| Female | 3881 (51%) | 3058 (55.4%) | 823 (39.5%) | ||||
| Male | 3722 (49%) | 2463 (44.6%) | 1259 (60.5%) | 4E-35 | |||
| Age (Mean ± SD) | 7606 | 70.7 ± 9.7 | 5523 | 70.4 ± 10 | 2083 | 71.5 ± 8.7 | 7E-6 |
| Age group (N, %) | 7606 | 5523 | 2083 | ||||
| ≤40 | 44 (0.6%) | 39 (0.7%) | 5 (0.2%) | 0.017 | |||
| 41-50 | 153 (2%) | 136 (2.5%) | 17 (0.8%) | 1E-6 | |||
| 51-60 | 832 (10.9%) | 653 (11.8%) | 179 (8.6%) | 4E-5 | |||
| 61-70 | 2589 (34%) | 1854 (33.6%) | 735 (35.3%) | 0.17 | |||
| 71-80 | 2758 (36.3%) | 1940 (35.1%) | 818 (39.3%) | 8E-4 | |||
| 81-90 | 1145 (15.1%) | 837 (15.2%) | 308 (14.8%) | 0.72 | |||
| >90 | 85 (1.1%) | 64 (1.2%) | 21 (1%) | 0.63 | |||
| Tissue specimen location (N, %) | 7606 | 5523 | 2083 | ||||
| Primary | 5352 (70.4%) | 3618 (65.5%) | 1734 (83.2%) | 4E-55 | |||
| Advanced | 1436 (18.9%) | 1203 (21.8%) | 233 (11.2%) | 7E-28 | |||
| Metastatic | 818 (10.8%) | 702 (12.7%) | 116 (5.6%) | 3E-21 | |||
| Unknown clinical stage (N, %) | 4975 (65.4%) | 3513 (63.6%) | 1462 (70.2%) | – | |||
| Known clinical stage (N, %) | 2631 (34.6%) | 2010 (36.4%) | 621 (29.8%) | – | |||
| Known clinical stage (N, %) | 2631 | 2010 | 621 | ||||
| Stage I | 301 (11.4%) | 246 (12.2%) | 55 (8.9%) | 0.021 | |||
| Stage II | 166 (6.3%) | 109 (5.4%) | 57 (9.2%) | 1E-3 | |||
| Stage III | 422 (16%) | 262 (13%) | 160 (25.8%) | 5E-13 | |||
| Stage IV | 1742 (66.2%) | 1393 (69.3%) | 349 (56.2%) | 3E-9 | |||
| Number of detected known pathogenic alterations (Mean ± SD) | 5781 | 3.9 ± 2.4 | 4190 | 3.8 ± 2.3 | 1591 | 4.2 ± 2.5 | 7E-8 |
| Genomic variants with known or potential clinical significance (N, %) | 7606 | 5523 | 2083 | ||||
| Guideline-indicated | 3328 (43.8%) | 3176 (57.5%) | 152 (7.3%) | 0 | |||
| Clinical trial or therapy in other tumor type | 5887 (77.4%) | 4385 (79.4%) | 1502 (72.1%) | 3E-11 | |||
| Neither above, but known pathogenic | 1641 (21.6%) | 1064 (19.3%) | 577 (27.7%) | 5E-15 | |||
| TMB (Mut/Mb) (Mean ± SD) | 6705 | 11 ± 11.1 | 4865 | 10.7 ± 11.3 | 1840 | 11.8 ± 10.6 | 2E-4 |
| TMB level (N, %) | 6705 | 4865 | 1840 | ||||
| Very high (≥20) | 841 (12.5%) | 645 (13.3%) | 196 (10.7%) | 4E-3 | |||
| High (10-19) | 2027 (30.2%) | 1258 (25.9%) | 769 (41.8%) | 1E-35 | |||
| Not high (<10) | 3837 (57.2%) | 2962 (60.9%) | 875 (47.6%) | 1E-22 | |||
| PD-L1 22C3 TPS (Mean ± SD) | 7558 | 22.2 ± 31.1 | 5487 | 22.7 ± 31.5 | 2071 | 21.1 ± 29.8 | 0.049 |
| PD-L1 level (N, %) | 7558 | 5487 | 2071 | ||||
| High (≥50%) | 1897 (25.1%) | 1416 (25.8%) | 481 (23.2%) | 0.022 | |||
| Low (1 - 49%) | 2848 (37.7%) | 1927 (35.1%) | 921 (44.5%) | 1E-13 | |||
| Negative (<1%) | 2813 (37.2%) | 2144 (39.1%) | 669 (32.3%) | 5E-8 | |||
| MSI level (N, %) | 6708 | 4863 | 1845 | ||||
| MSI High | 23 (0.3%) | 9 (0.2%) | 14 (0.8%) | ||||
| Stable | 6685 (99.7%) | 4854 (99.8%) | 1831 (99.2%) | 1E-3 | |||
N, number of cases with data for variable; SD, the standard deviation of the mean; TMB, tumor mutational burden, measured as mutations per megabase (Mut/Mb); TPS, tumor proportion score (i.e., the proportion of tumors positive for PD-L1 immunohistochemistry with 22C3 antibody as observed by a pathologist); MSI, microsatellite instability score; P, uncorrected P-value from testing differences between adenocarcinoma and squamous cell carcinoma using Fisher’s exact test or linear regression for categorical or quantitative variables, respectively.